GABA-Dabba Do or Don’t? Gabapentin for Non-Neuropathic Pain
This activity will provide brief teaching regarding the history of gabapentin’s FDA approval and the emergence of its multiple off-label uses. Next, clinical trials will be reviewed that have investigated the use of gabapentin for non-neuropathic pain in addition to a review of the risks associated with gabapentin therapy. The activity will conclude with a summary of which non-neuropathic pain syndromes in which gabapentin should be considered. The primary purpose of session is to disseminate information regarding gabapentin for non-neuropathic in hopes that there will be an improvement in patient pain-related outcomes.
- Describe the pharmacology of gabapentin
- Recognize the initial FDA approved indication for gabapentin and development of off-label indications
- Analyze the literature evaluating gabapentin for non-neuropathic pain
- Formulate recommendations for the use of gabapentin in non-traditional settings
Pharmacy technician learning objectives
- Discuss the common uses for gabapentin
- Describe the role of gabapentin in the management of non-neuropathic pain
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
Ineligible companies – those companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
FDA Off-Label Use
Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.
Absence of Relevant Financial Relationships
The following planners, faculty, and others in control of educational content have no relevant financial relationships with ineligible companies.
Zachary Kim, PharmD
Planning committee and speaker
PGY-1 Pharmacy Practice Resident
Amy Breeding, PharmD
Joint Accreditation Statement:
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and ChristianaCare. Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number(s): JA0006103-9999-22-006-L01-P and JA0006103-9999-22-006-L01-T
Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician